Nucleix Ltd., of Rehovot, Israel, received €2.5 million (US$2.9 million) in funding from the European Innovation Council's (EIC) pilot SME Instrument phase II program. EIC pilot SME Instrument phase II is part of Horizon 2020, an €80 billion funding program managed by the European Commission that is dedicated to innovation and research. Nucleix received the funding for its Lung Epicheck, a screening diagnostic blood test for early detection of lung cancer. The test is based on molecular biomarker technology, which combines new biochemical assays and algorithms.

No Comments